---
title: "Why Is Avidity Biosciences Stock (RNA) Down Today?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277213257.md"
description: "Avidity Biosciences (RNA) stock fell after shareholders approved a merger with Novartis (NVS), which includes spinning off some assets into a new company, Atrium Therapeutics. The merger's timing has caused confusion, leading to volatility in RNA stock as it may be removed from public markets. Investors are advised to be cautious until the effects of the merger are fully reflected."
datetime: "2026-02-27T14:07:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277213257.md)
  - [en](https://longbridge.com/en/news/277213257.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277213257.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277213257.md) | [繁體中文](https://longbridge.com/zh-HK/news/277213257.md)


# Why Is Avidity Biosciences Stock (RNA) Down Today?

Avidity Biosciences (RNA) stock appeared to plummet on Friday after the RNA-focused biopharmaceutical company's shareholders voted to approve a merger with Novartis (NVS). This agreement will also see certain assets of Avidity Biosciences spun off into a separate company, which will be named Atrium Therapeutics.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

The decision to complete the merger with Novartis has resulted in chaos for RNA stock this morning. The company had to reconvene a special shareholder meeting earlier this week to prepare for the deal. That included giving the company enough time to distribute issued and outstanding shares of Atrium Therapeutics.

Additionally, the timing of the merger is causing confusion this morning, as the merger went into effect today. This should see Avidity Biosciences stock removed from the public market and replaced with Atrium Therapeutics. As such, investors can expect volatility until the full effects of the merger are reflected on public markets.

## **Avidity Biosciences Stock Movement Today**

As noted, it's unclear if Avidity Biosciences stock is actually down today, or if public listings haven't caught up to the merger agreement with Novartis. As such, traders will want to be careful about making any moves with the company's stock until this is all sorted out.

### Related Stocks

- [Novartis AG (NVS.US)](https://longbridge.com/en/quote/NVS.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [Atrium Therapeutics, Inc. (RNA.US)](https://longbridge.com/en/quote/RNA.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Novartis Shareholders Approve Dividend Raise, Share Capital Reduction](https://longbridge.com/en/news/278130521.md)
- [Tritonpoint Wealth LLC Sells 10,771 Shares of Zoetis Inc. $ZTS](https://longbridge.com/en/news/281684930.md)
- [FDA Approves Dosing Interval Extension Up To 20 Weeks For EYLEA HD In WAMD And DME](https://longbridge.com/en/news/281744271.md)
- [BMS, Novartis, Gilead, Iovance dinged in CBER untitled letters](https://longbridge.com/en/news/281059389.md)
- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/en/news/281346305.md)